CIRC is the national IBD research consortium of Canada. The aim of this association is to promote collaboration IBD research among Canadian investigators. CIRC currently is composed of over 60 gastroenterologists with IBD research interest throughout Canada.
Dr. Sanjay Murthy, MD, MSc, FRCPC, CIRC Director of Research
Associate Professor of Medicine, University of Ottawa Associate Scientist, Ottawa Hospital Research Institute Staff Gastroenterologist, The Ottawa Hospital IBD Centre
Dr. Murthy is an Associate Professor, Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, and a Clinician-Investigator in the Division of Gastroenterology at the University of Ottawa. He is a member of The Ottawa Hospital IBD Centre and Director of the home parenteral nutrition program. He completed his medical degree at the University of Ottawa, Internal Medicine Residency at the University of Manitoba and Gastroenterology Residency at the University of Toronto. He has completed advanced fellowships in IBD (Mount Sinai Hospital, Toronto), clinical nutrition (Toronto General Hospital) and endoscopy (Mainz, Germany), and a M.Sc. in Clinical Epidemiology and Health Care Research (University of Toronto). His research program uses clinical and health administrative data to study the quality and effectiveness of current practice and to develop models for personalized medicine, which he applies to the study of IBD and colorectal cancer prevention.
Dr. Daniel C. Baumgart, MD PhD MBA FACP FRCP (Lon) AGAF
University Professor and Director, Division of Gastroenterology, Director of the Inflammatory Bowel Disease Unit at the University of Alberta
Daniel C. Baumgart, MD PhD MBA FACP FRCP (Lon) AGAF is University Professor and Director, Division of Gastroenterology, Director of the Inflammatory Bowel Disease Unit at the University of Alberta in Edmonton and Alberta Health Services (AHS) Section Head for the Edmonton Zone.
Dr. Baumgart is serving on the editorial boards of The Lancet and Gut, as elected executive board member of the German IBD Compentence Network within the German Society for Gastroenterology (DGVS), as well as author of many European Crohn’s and Colitis Organization (ECCO) and other professional society guidelines.
Dr. Baumgart has been principal investigator and/or national coordinator in some 200 multinational clinical trials. A trailblazer of digitization he has a strong interest in digital health, artificial intelligence (AI), decision support and machine learning ultimately aiming to provide precision medicine at the point of care.
Dr. Frank Hoentjen, MD, PhD
Associate Professor of Medicine, Division of Gastroenterology at the University of Alberta
Dr. Frank Hoentjen is a Gastroenterologist and Associate Professor of Medicine, Division of Gastroenterology at the University of Alberta. He completed his residencies and GI fellowship at the Free University Medical Center, Amsterdam, completed an advanced IBD fellowship at the University of Chicago, USA, and his PhD was awarded by the Free University Medical Center, Amsterdam following a research fellowship at the University of North Carolina at Chapel Hill, USA. In 2011 he joined the Gastroenterology faculty at the Radboud University Medical Center Nijmegen, The Netherlands until 2021.
Dr. Hoentjen was director of the Inflammatory Bowel Center and director of the GI clinical trial unit at the Radboud University Medical Center Nijmegen, The Netherlands. He was chair of the Initiative on Crohn and Colitis (ICC), the Dutch national organization for IBD research. Dr. Hoentjen founded and chaired the nation-wide Dutch IBD registry, IBDREAM. He was member of the IBD committee of the Dutch National Association for Gastroenterology (NVMDL) and the Dutch national IBD guideline committee in the Netherlands. His research aims include (1) optimization of immunosuppressive and biological therapies through clinical and translational studies, and (2) achieve a better understanding of the risk of colorectal cancer and dysplasia in IBD patients and improve surveillance strategies to prevent cancer.
Dr. Vivian Huang, MSc, MD, FRCPC
Assistant Professor and Clinician Investigator in the Division of Gastroenterology at Mount Sinai Hospital & the University of Toronto
Dr. Huang is an Assistant Professor and Clinician Investigator in the Division of Gastroenterology at Mount Sinai Hospital & the University of Toronto. She completed medical school and internal medicine residency at Queen’s University, and Gastroenterology fellowship at the University of Toronto. Funded by Alberta Innovates Health Solutions clinician research fellowship, she obtained an Advanced IBD clinical research fellowship and Masters of Science (Medicine) at the University of Alberta, where she developed the Northern Alberta Preconception and Pregnancy in IBD clinical research program (2015 to 2017). After moving to Mount Sinai Hospital, Toronto in 2017, she established the Preconception and Pregnancy in IBD clinical research program for Toronto and Ontario. Her primary clinical research interests include using multidisciplinary approaches and e-health strategies to incorporate P4 (predictive, preventive, participatory, personalized) medicine to optimize maternal, fetal, and neonatal outcomes in IBD, and conducting translational studies investigating the impact of maternal IBD and therapies on the fetus and neonate.
Dr. Reena Khanna, MD MSc FRCPC
Associate Professor of Medicine, Department of Medicine, Division of Gastroenterology, University of Western Ontario, London Ontario Canada
Dr. Reena Khanna is an Associate Professor of Medicine at the University of Western Ontario, and a Clinician Researcher in the Program for Experimental Medicine. She completed her MD and Internal Medicine residency at the University of Western Ontario, Gastroenterology fellowship at McMaster University. Dr. Khanna completed an advanced fellowship in inflammatory bowel disease (IBD) at the Cleveland Clinic, followed by a research fellowship in international IBD clinical trials at the University of Western Ontario. She completed an MSc in clinical epidemiology at McMaster University. Her clinical and research interest are clinical trial design, new therapeutics, outcome measures. She has designed, conducted and published several studies, including the first cluster study in IBD. Dr. Khanna holds international grants and most recently was awarded the Crohn’s Colitis Canada’s rising star award for her research contributions.
Dr. Peter Lakatos, MD, PhD, DSc, FEBG, AGAF
Director of IBD Centre, Associate Professor, McGill University, MUHC, Montreal General Hospital
Dr. Lakatos is an associate professor and director of IBD Centre at McGill University, MUHC. Until January 2017, he was head of the gastroenterology/hepatology ward, endoscopy unit and outpatient clinic at the 1st Department of Medicine, Semmelweis University in Budapest, Hungary. He is one of the founders and leader of the Hungarian IBD Study Group, council member of the Hungarian Society for Gastroenterology and president elect of the Colon Section. He is a member of the educational committee in ECCO and IOIBD member. He is a regular reviewer in leading international journals in gastroenterology/hepatology, section editor in Inflammatory Bowel Diseases, BMC Gastroenterology and associate editor in J Crohn’s Colitis and World Journal of Gastroenterology. During his career, he has published more than 250 original papers and reviews, including 25 book chapters. His primary research interest is the epidemiology, outcome and biomarkers in the prediction of disease progression and response to medical therapy in IBD.
Dr. Harminder Singh, MD MPH
Associate Professor of Medicine, Dept. of Internal Medicine and Community Health Sciences, College of Medicine, Faculty of Health Sciences, University of Manitoba
Dr. Harminder Singh received his MBBS and MD from All India Institute of Medical Sciences and Masters of Public Health from the University of Manitoba. He received training in gastroenterology, IBD, gastrointestinal oncology and health outcomes research at University of Manitoba. He is currently an Associate Professor of Medicine, Dept. of Internal Medicine and Community Health Sciences, College of Medicine, Faculty of Health Sciences, University of Manitoba. He is a former member of the Canadian Task Force on Preventive Health Care, an organization developing and disseminating clinical practice guidelines for primary care. He is a clinician scientist, epidemiologist and practicing gastroenterologist.
Dr Singh is a member of the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC), and a co-author on the Steering Committee of the 2018 Burden of IBD Report for Crohn’s and Colitis Canada (Journal of the Canadian Association of Gastroenterology 2019). He has expertise in using administrative health care datasets to answer a variety of questions, including assessment of outcomes among individuals with inflammatory bowel disease.
Dr. Singh’s research interests have been varied and include clinical epidemiology, pharmaco-epidemiology and health services research. Dr. Singh has lead studies on epidemiology and prevention of colorectal cancer. He has lead studies assessing health care outcomes among individuals with IBD, including skin cancers, cervical cancer precursors, colorectal cancer, screening for cancers, risk of clostridium difficile infections, educational outcomes among those with IBD and care of elderly with IBD. He has lead knowledge translation studies to improve processes around colonoscopy, an essential test to diagnosis and manage those with IBD.
Adam V. Weizman, MD, MSc, FRCPC
Associate Professor of Medicine, University of Toronto, Division of Gastroenterology, Mount Sinai Hospital.
Dr. Weizman is a gastroenterologist at Mount Sinai Hospital in Toronto, Ontario and an Associate Professor of Medicine at the University of Toronto. He received his medical degree from the University of Manitoba and subsequently did a Residency in Internal Medicine and Fellowship in Gastroenterology at the University of Toronto. He completed the Advanced Fellowship in Inflammatory Bowel Diseases at Cedars-Sinai Medical Center in Los Angeles, California and a Master’s degree (MSc) in Quality Improvement and Patient Safety from the Institute of Health Policy, Evaluation, and Management at the University of Toronto. His research interests include healthcare quality and health outcomes, with a focus on inflammatory bowel disease (IBD). Dr. Weizman is the Medical Director of the Centre for Inflammatory Bowel Disease at Mount Sinai Hospital and Head of Quality and Patient Safety for the Division of Gastroenterology at Mount Sinai Hospital and the University Health Network.